GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Qualitative Analysis of Subject Experience of Nasal Polyps

Completed

Conditions: Nasal Polyps

Interventions: Other: VAS questionnaire
Other: SNOT-22 questionnaire
Other: Data capture app

First Posted Date: 2017-07-18

Last Posted Date: 2019-05-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 27

Registration Number: NCT03221192

Locations: 🇺🇸
GSK Investigational Site, Boston, Massachusetts, United States

RELVAR® 100 ELLIPTA® Special Drug Use Investigation (COPD, Long-term)

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: RELVAR 100 ELLIPTA

First Posted Date: 2017-07-17

Last Posted Date: 2021-07-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1047

Registration Number: NCT03219255

Locations: 🇯🇵
GSK Investigational Site, Kanagawa, Japan

A Proof of Concept Clinical Study to Investigate the Effects of an Experimental Cosmetic Moisturiser on the Barrier Function of Human Skin on the Face and Forearm

Not Applicable

Completed

Conditions: Skin Care

Interventions: Other: Test product (Moisturising cream)
Other: No treatment
Other: Positive control (Commercial market place moisturising cream)

First Posted Date: 2017-07-13

Last Posted Date: 2019-04-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 69

Registration Number: NCT03216265

Locations: 🇩🇪
GSK Investigational Site, Schenefeld, Schleswig-Holstein, Germany

Study of Renin-angiotensin System in Mechanically Ventilated Subjects

Not Applicable

Terminated

Conditions: Acute Lung Injury

Interventions: Drug: Local standard of care
Procedure: Mechanical ventilation

First Posted Date: 2017-07-11

Last Posted Date: 2020-04-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 57

Registration Number: NCT03212690

Locations: 🇫🇷
GSK Investigational Site, Créteil, France

This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

Phase 3

Completed

Conditions: Rotavirus Vaccines
Rotavirus Infection

Interventions: Biological: Rotarix
Biological: Pediarix
Biological: Hiberix
Biological: Prevenar 13

First Posted Date: 2017-07-05

Last Posted Date: 2020-12-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1280

Registration Number: NCT03207750

Locations: 🇺🇸
GSK Investigational Site, Marshfield, Wisconsin, United States

Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: GSK3772847
Drug: Placebo
Drug: Fluticasone propionate/salmeterol
Drug: Fluticasone propionate

First Posted Date: 2017-07-02

Last Posted Date: 2020-03-02

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 165

Registration Number: NCT03207243

Locations: 🇺🇦
GSK Investigational Site, Kyiv, Ukraine

A Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of GSK2894512 in Healthy Adult Subjects

Phase 1

Withdrawn

Conditions: Psoriasis

Interventions: Drug: GSK2894512 1% CREAM
Drug: GSK2894512 MATCHING VEHICLE CREAM

First Posted Date: 2017-06-28

Last Posted Date: 2017-11-29

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT03201978

A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults

Phase 1

Completed

Conditions: Respiratory Disorders

Interventions: Biological: Blood sampling
Biological: GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, PE-PilA and UspA2.
Biological: GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2.
Drug: Placebo